AVDEL UK LIMITED

Company number 00315076 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment: AVDEL UK LIMITED

1. Financial Health Score: B+ This score reflects a patient with an exceptionally strong constitution and robust structural support, albeit one whose vital signs are heavily reliant on a larger parent system. The company benefits from a very long lifespan, perfect regulatory health (compliance), and a massive capital base. However, the lack of visible, detailed circulatory metrics (cash flow, liquidity) and the absolute control by a holding company mean it lacks financial autonomy, making its health partially dependent on the wellness of its parent.


2. Key Vital Signs

  • Longevity & Resilience (Incorporated: 1936-06-11): This patient has an 88-year medical history. Surviving nearly a century of economic cycles indicates incredible genetic resilience and a business model that can adapt. This long lifespan provides significant operational stability.
  • Regulatory Pulse (Filings & Compliance): The company’s heartbeat is strong and regular. Accounts are filed up to date (made up to 31 Dec 2024, not overdue) and confirmation statements are current. There are no signs of administrative arrhythmia; the company is breathing steadily and meeting all its statutory obligations.
  • Skeletal Strength (Share Capital): The share capital stands at a staggering £39,068,092.40. In medical terms, this represents extraordinary "bone density." For a private limited company in the manufacturing sector, this level of share capital suggests either massive historical retained earnings that have been capitalized, or significant capital injections from the parent company. It provides a formidable buffer against operational shocks.
  • Corporate DNA (Ownership & Control): Avdel Holding Limited owns more than 75% of the shares, holds more than 75% of the voting rights, and has the right to appoint and remove directors. This company does not operate as an independent organism; it is a wholly-owned subsidiary whose blood supply and nervous system are managed by a larger corporate body.
  • Medical History (Previous Names): The history of name changes (Avdel Limited to Avdel Systems, to Avdel Textron, to Textron Fastening Systems, and back to Avdel UK) shows a patient that has undergone several major corporate "surgeries" or rebranding, most notably a past integration with Textron, a massive US conglomerate. The reversion to the Avdel name in 2006 suggests a subsequent spin-off or divestment.

3. Diagnosis

Diagnosis: Stable, Subsidiary Dependent, with High Capital Reserves

Avdel UK LIMITED presents as a structurally robust but non-autonomous entity. The most prominent symptom is the £39 million share capital, which acts as a massive financial immune system. However, because the company is under the absolute control of Avdel Holding Limited, its financial wellness is inextricably linked to the "parent organism."

Without the detailed blood work (Profit & Loss, current assets vs. current liabilities), it is impossible to measure the company's independent respiratory function (liquidity) or metabolic efficiency (profitability). The recent resignation of Director name shown to subscribers (noted in the data as 2026, likely a filing anomaly or pending future effective date) and the current stewardship of Directors name shown to subscribers and name shown to subscribers suggest an ongoing evolution of the corporate brain trust. Ultimately, the company is healthy enough to survive, but its strategic direction is entirely dictated by the holding company's central nervous system.


4. Recommendations

  • Monitor the Parent's Vitals: Because Avdel UK is wholly owned and controlled by Avdel Holding Limited, any financial distress at the holding company level will immediately be transmitted to this entity. Regular cardiovascular checks on the parent company's financial statements are essential.
  • Examine the Blood Flow (Cash Flow): While the £39M share capital provides a thick safety cushion, high share capital alone doesn't guarantee healthy cash flow. The business should ensure that working capital (current assets minus current liabilities) remains positive and that inter-company loans or debts to the parent are not draining the company's liquidity.
  • Maintain Regulatory Health: The company currently has an excellent compliance record. Continuing to file accounts and confirmation statements on time is vital to prevent statutory penalties, which could act as unnecessary stressors on an otherwise healthy system.

Names of the people mentioned are shown to subscribers. See subscription

Perspective: Financial Health Diagnostician · Model: glm-5.1 · Generated 1 September 2026